Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

FDA Hold Review Continues As Newron Advances Phase 3 Evenamide Program

(RTTNews) - Newron Pharmaceuticals (NP5.DE) said the FDA has provided written feedback regarding the clinical hold affecting U.S. sites in its Phase 3 ENIGMA-TRS 2 study of evenamide, and the company is preparing a response.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Source: nasdaq.com

Read the original at nasdaq.com →

Report a problem with this story

More in Health & Medicine

More from Thursday 8 October →